中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案)[J]. 中华结核和呼吸杂志, 2003, 26(3): 132-136. Bronchial Asthmatic Group of Respiratory Medicine Branch of Chinese Association. The Chinese medical association respiratory epidemiology (Bronchial asthmatic diagnosis and treatment guidelines) [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2003, 26(3): 132-136.
[2]
巴克·阿里木阿吉. 维吾尔医诊断学[M]. 乌鲁木齐: 新疆人民卫生出版社, 2012: 111-120. Alemajim Bak. Uighur medical diagnostics[M]. Urumqi: Xinjiang People's Medical Publishing House, 2012: 111-120.
[3]
哈木拉提·吾甫尔. 维吾尔医气质、体液论及其现代研究[M]. 乌鲁木齐: 新疆科学技术出版社, 2003: 40-47. Upur Halmurat. Theory of mizaj and hilit in uighur medicine and mordern study[M]. Urumqi: Xinjiang Science and Technology Publishing House, 2003: 40-47.
[4]
Dunn E J, Grant P J. Type 2 diabes: Anatherothrombotic syndrome[J]. Current Molecular Medicine, 2005, 5(3): 323-332.
[5]
Lip G Y, Edmunds E, Beevers D G. Should patients with hyper-tension receive antithrombotic therapy?[J]. Journal of Internal Medicine, 2001, 249(3): 205-214.
Korbut R, Gryglewski R J. The effect of prostacyclin and nitric oxide on deformability of red blood cells in septic shock in rats[J]. Physiology and Pharmacology, 1996, 47(4): 591-599.
[8]
Baskurt O K, Gdmont D, Meiselman H J. Red blood cell deformability in sepsis[J]. American Journal of Respiratory and Critical Care Medicine, 1998, 157: 421-427.
[9]
武焕玲, 林隆玖. 血栓前状态研究进展[J]. 中国实验诊断学, 2003, 7 (4): 277-280. Wu Huanling, Lin Longjiu. The reviewed of prethromboticseate[J]. Chinese Journal of Laboratory Diagnosis, 2003, 7(4): 277-280.
[10]
李家增. 血管血栓性疾病的发病机制和防治[J]. 基础医学与临床,2006, 26(6): 561-565. Li Jiazeng. Pathogenic mechanism and treatment of vascular thromboenbolismdisease[J]. Basic Medical Sciences and Clinics, 2006, 26 (6): 561-565.
[11]
Ferguson J J, Waly H M, Wilson J M. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition[J]. European Heart Journal, 1998, 19(S1): D3.
[12]
徐宜, 孙文学. 老年糖尿病肾病血小板活化分子检测的意义[J]. 黑龙江医学, 2004, 28(1): 26-28. Xu Yi, Sun Wenxue. Significance of detection of platelet activation markers in elderly diabetic nephropathy[J]. Heilongjiang Medical Journal, 2004, 28(1): 26-28.
[13]
Zizzi H C, Zibari G B, Granger D N, et al. Quantification of P-selectin expression after renal ischemia and reperfusion[J]. Journal of Pediatric Surgery, 1997, 32(7): 1010-1013.
[14]
Miamino T, Kitakase M, Sanada S, et al. Increased expression of P-selection on platelets is a risk factor for silent cerebalinfaction in patients with atrial fibrillation[J]. Circulation, 1998, 98(3): 1721-1727.
[15]
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature, 1988, 332(6163): 411-415.
[16]
陶连方. 老年高血压病糖尿病患者血浆内皮素测定及其意义[J]. 中国微循环, 2003, 7(4): 245. Tao Lianfang. Significance of detection of plasma endothelium in elderly diabetic nephropathy and hypertension[J]. Journal of Chinese Microcirculation, 2003, 7(4): 245.
[17]
Nguyen-Ho P, Lakkis N M. Platelet glycoprotein IIb/IIIa a receptor antagonists and coronary disease[J]. Current Atherosclerosis Reports, 2001, 3(2): 139-148.
[18]
王振义, 李家增, 阮长耿, 等. 纤维蛋白溶解系统[C]//上海第二医科大学编辑委员会. 血栓与止血基础理论与临床. 2版. 上海: 上海科学技术出版社, 1996. Wang Zhenyi, Li Jiazeng, Ruan Changgeng, et al. Fibrinolytic system[C]//Editorial Committee of Shanghai Second Medical University. The Basic Theory and Clinical of Thrombosis and Haemostasis. 2nd ed. Shanghai: Shanghai Science and Technology Publishing House, 1996.
[19]
丛玉隆, 王淑娟, 朱士俊, 等. 纤溶系统的组成及特点[C]//今日临床检验学编辑委员会编. 今日临床检验学. 北京: 中国科学技术出版社, 1997. Cong Yulong, Wang Shujuan, Zhu Shijun, et al. The composition and the characteristics of fibrinolytic system[C]//Today Clinical Inspection Editorial Board. Today Clinical Test. Beijing: China Science and Technology Publishing House, 1997.
[20]
Bernd R B, Gunter C, Florian G, et al. Plasminogen activator inhibitor physiological and pathophysiological roles[J]. Newsin Physiological Sciences, 2002, 17: 56-61.
[21]
葛郁芝, 刘冬生. 高血压病患者血栓前状态P-选择素等标志物变化及其临床意义[J]. 中国心血管病研究杂志, 2005, 3(12): 896-899. Ge Yuzhi, Liu Dongsheng. Levels of P selection and its clinic significance in hypertensive patients with prothromboticstatus[J]. Chinese Journal of Cardiovascular Review, 2005, 3(12): 896-899.
[22]
Qizilbash N, Duffy S, Prentice C R M, et al. Willebrand factor and risk of ischemic stroke[J]. Neurology, 2001, 53(6): 1552-1556.
[23]
Yamell J W G, Baker I A. Sweetnam P M, et al. Fibrinogen, viscosity and white blood cell count are major risk factor for ischemic heart disease[J]. Circulation, 1991, 83: 836.
[24]
居来提·托乎提, 阿不都克热木江·吐尔逊托乎提. 维吾尔医学对哮喘病因的认识[J]. 中国民族医学杂志, 2004, 10(4): 3-4. Tuohuti Julaiti, Tuerxuntuohuti Abudukeremujian. Recognize on the Uygur traditional medicine for asthma cause[J]. Journal of Medicine & Pharmacy of Chinese Minorities, 2004, 10(4): 3-4.
[25]
Bauer K A, Rosenberg R D. The pathophysiology of the perthrombotic state in humans: Insights gained from stadies using markers of hemostatic system activation[J]. Blood, 1987, 70(2): 343-350.
[26]
常玉荣, 杨德全, 唐福美, 等. 血栓栓塞性疾病血栓前状态的实验室诊断[J]. 中国综合临床, 2001, 17(2): 83. Chang Yurong, Yang Dequan, Tang Fumei. Thromboembolic disease before thrombus state laboratory diagnosis[J]. Clinical Medicine of China, 2001, 17(2): 83.
[27]
Beather E, LichtmanM A, Coller B S, et al. Hematollgy[M]. 6th ed. New York: McGraw Hill, 2001: 1735-1763.
[28]
宗俊学, 芦璐, 徐洪玉. 血栓前状态与高血压病的关系[J]. 血栓与止血学, 2005, 11(1): 21-23. Zong Junxue, Lu Lu, Xu Hongyu. The relationship between prethromboticseate and hypertension[J]. Chinese Journal of Thrombosis and Hemostasis, 2005, 11(1): 21-23.
[29]
Falanga A, Tickles F R. Pathophysiology of the thrombophilic state in the cancer patient[J]. Seminars in Thromband Hemostasis, 2002, 25(2): 173-182.
[30]
Sarkar R R, Banerjee S. Cancer self remission and tumor stability a stochastic approach[J]. Mathematical Biosciences and Engineering, 2005,196(1): 65-81.
[31]
CalveteJ J. Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoproteinIIb/III acomplex[J]. Thrombosis andHaemostasis, 1994, 7(1): 11-16.
[32]
Egidy G, Juillerat J L, Jeannin J F, et al. Modulation of human colon tumor-stromalinter actions by the endothelin system[J]. American Journalof Pathology, 2000, 157(6): 1863-1874.
[33]
Calvete J J. Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoproteinIIb/III acomplex[J]. Thrombosis and Haemostasis, 1994, 7(1): 11-16.
[34]
Erlandsen S L, Bittermann A G, White J, et al. High-resolutioncryofesemof individual cell adhesion molecules (CAMs) in theglycocalyx of human platelets: Detection of P-selectin(CD62P), GPI-IX complex (CD42a/CD42b, b？), and integrin GPIIb/IIIa(CD41/CD61) byimmunogold labeling and stereo imaging[J]. Journal of Histochemistry and Cytochemistry, 2001, 49(7): 809-819.
[35]
Suzuki S, Hayashi Y, Wang Y, et al. Urokinase type pkasminogen activator receptor expression in colorectal neoplasms[J]. Gut, 1998, 43(6): 798-805.
[36]
哈木拉提·吾甫尔. 维吾尔医学气质、体液论及其现代研究[M]. 乌鲁木齐: 新疆科学技术出版社, 2003, 7: 75-77. Upur Halmurat. Theory of mizaj and hilit in Uighur medicine and mordern study[M]. Urumqi: Xinjiang Science and Technology Publishing House, 2003, 7: 75-77.
